For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?

Journal of Family Practice

Volumn 54, Issue 8, 2005, Pages 711-713

  Penmetsa, Santhi ^a   Simmons, Michael ^b  

^a BAYLOR UNIVERSITY   (United States)

^b Michigan State University and Sparrow Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; VERAPAMIL; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; HYPERTENSION; PROTEINURIA; REVIEW; SUSTAINED RELEASE PREPARATION; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; DIURETICS; HUMANS; HYPERTENSION;

EID: 23444456272     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Molitech ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1):S79-S83.
2. Abbott K, Basta E, Bakris GL. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol 2004; 44:431-438.
3. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
6. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression : a systematic review. Kidney Int 2004; 65:1991-2002.
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS38). UK Prospective Diabetes Study Group. BMJ 1998; 317:703-713.
8. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized control trial. Ann Intern Med 1997; 126:955-959.
9. Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22:1613-1622.
10. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of protein restriction on the progression diabetic and nondiabetic renal diseases: a meta analysis. Ann Intern Med 1996; 124:627-632.
11. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319-327.
12. Standards of Medical Care in Diabetes. Diabetes Care 2005; 28(Suppl-1):S4-S36.